SOHO 2026 | New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera
• 14 Sep 2026
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses emerging therapeutic approaches for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Prof. Ribera highlights that newer bispecific agents may further improve efficacy, tolerability, and ease of administration, with the potential of making long-term survival achievable for most adults with Ph+ ALL. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
